Evidence map›Paper›PMID 25394490›Full record

ArticleCell death and differentiation2015

GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

J J Credle, J L George, J Wills, V Duka, K Shah, Y-C Lee, O Rodriguez, T Simkins, M Winter, D Moechars and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell death and differentiation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 115 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Neuroprotection of engineeredJournal of Zhejiang University. Science. B · 2026
    Article
  6. Review
  7. 25International journal of molecular sciences · 2026
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

J J CredleDepartment of Biochemistry, Georgetown University, Washington, D.C., USA.
J L GeorgeFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Vic, 3010, Australia.
J WillsDepartment of Biochemistry, Georgetown University, Washington, D.C., USA.
V DukaDepartment of Biochemistry, Georgetown University, Washington, D.C., USA.
K ShahDepartment of Biochemistry, Georgetown University, Washington, D.C., USA.
Y-C LeeDepartment of Oncology, Georgetown University, Washington, D.C., USA.
O RodriguezDepartment of Oncology, Georgetown University, Washington, D.C., USA.
T SimkinsDepartment of Neurology, Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI, USA.
M WinterDepartment of Biochemistry, Georgetown University, Washington, D.C., USA.
D MoecharsJanssen Research & Development, a division of Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse, 2340, Belgium.
T StecklerJanssen Research & Development, a division of Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse, 2340, Belgium.
J GoudreauDepartment of Neurology, Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI, USA.
D I FinkelsteinFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Vic, 3010, Australia.
A SidhuDepartment of Biochemistry, Georgetown University, Washington, D.C., USA.
Georgetown University · USFlorey Institute of Neuroscience and Mental Health · AUMichigan State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant posttranslational modifications (PTMs) of proteins, namely phosphorylation, induce abnormalities in the biological properties of recipient proteins, underlying neurological diseases including Parkinson's disease (PD). Genome-wide studies link genes encoding α-synuclein (α-Syn) and Tau as two of the most important in the genesis of PD. Although several kinases are known to phosphorylate α-Syn and Tau, we focused our analysis on GSK-3β because of its accepted role in phosphorylating Tau and to increasing evidence supporting a strong biophysical relationship between α-Syn and Tau in PD. Therefore, we investigated transgenic mice, which express a point mutant (S9A) of human GSK-3β. GSK-3β-S9A is capable of activation through endogenous natural signaling events, yet is unable to become inactivated through phosphorylation at serine-9. We used behavioral, biochemical, and in vitro analysis to assess the contributions of GSK-3β to both α-Syn and Tau phosphorylation. Behavioral studies revealed progressive age-dependent impairment of motor function, accompanied by loss of tyrosine hydroxylase-positive (TH+ DA-neurons) neurons and dopamine production in the oldest age group. Magnetic resonance imaging revealed deterioration of the substantia nigra in aged mice, a characteristic feature of PD patients. At the molecular level, kinase-active p-GSK-3β-Y216 was seen at all ages throughout the brain, yet elevated levels of p-α-Syn-S129 and p-Tau (S396/404) were found to increase with age exclusively in TH+ DA-neurons of the midbrain. p-GSK-3β-Y216 colocalized with p-Tau and p-α-Syn-S129. In vitro kinase assays showed that recombinant human GSK-3β directly phosphorylated α-Syn at a single site, Ser129, in addition to its known ability to phosphorylate Tau. Moreover, α-Syn and Tau together cooperated with one another to increase the magnitude or rate of phosphorylation of the other by GSK-3β. Together, these data establish a novel upstream role for GSK-3β as one of several kinases associated with PTMs of key proteins known to be causal in PD.

Indexed as

alpha-SynucleinAnimalsGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansMiceMice, TransgenicParkinsonian Disorderstau Proteinsalpha-SynucleinGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGSK3B protein, humanGsk3b protein, mouseMAPT protein, humanMapt protein, mousetau Proteins

Identifiers

PMID25394490
PMCPMC4392080
OpenAlexW2040691826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.